Revenue
2022
2023
2024
2025
Coya Therapeutics, Inc. (COYA)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Research & development | $16.7M | $11.9M | $5.5M | $4.4M | $2.5M |
| Operating expenses | $30.5M | $20.8M | $13.9M | $9.8M | $4.9M |
| Operating income | −$22.6M | −$17.2M | −$7.9M | −$9.8M | −$4.9M |
| Net income | −$21.2M | −$14.9M | −$8.0M | −$12.2M | −$4.9M |
| Basic EPSper diluted share | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
| Diluted EPSper diluted share | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 14, 2024Form 4 | SNYDER DAVID SChief Financial Officer | BuyCommon Stock, par value $0.0001 per share | 1.8K | $7.19 | $12.9K | 8.8K |
| Nov 13, 2024Form 4 | Swaminathan ArunChief Executive Officer | BuyCommon Stock, par value $0.0001 per share | 5.0K | $7.36 | $36.8K | 10.0K |
| Nov 11, 2024Form 4 | Grossman FredChief Medical Officer | BuyCommon Stock, par value $0.0001 per share | 2.7K | $7.37 | $20.0K | 2.7K |
| Nov 11, 2024Form 4 | Swaminathan ArunChief Executive Officer | BuyCommon Stock, par value $0.0001 per share | 5.0K | $7.34 | $36.7K | 5.0K |